Age, yr | 26.1 ± 3.9 | 25.6 ± 5.5 | 28.4 ± 5.1 | 24.1 ± 4.2 | Users v. nonusers† |
Education, yr | 15.1 ± 2.1 | 12.8 ± 1.6 | 12.8 ± 2.0 | 10.2 ± 1.9 | Patients v. controls‡; Users v. nonusers‡ |
Single marital status, no. (%) | 6 (40) | 13 (65) | 12 (80) | 16 (80) | Patients v. controls† |
Mo. since treatment onset, mean ± SD (range) | — | — | 34.6 ± 29 (1–110) | 25.6 ± 26 (3–105) | None |
Chlorpromazine equivalents prescribed | — | — | 315 ± 200 | 236 ± 85 | None |
Other psychiatric meds prescribed, no. (%) | — | — | 4 (27) | 3 (15) | None |
Diagnosis, schizophrenia:schizoaffective disorder | — | — | 15:0 | 16:4 | None |
SAPS global total score | — | — | 5.2 ± 4.7 | 3.2 ± 2.3 | None |
SANS global total score | — | — | 5.9 ± 3.7 | 7.5 ± 4.0 | None |
SANS anhedonia global score | — | — | 1.9 ± 1.5 | 2.2 ± 1.4 | None |
SANS avolition global score | — | — | 2.4 ± 1.4 | 3.1 ± 1.3 | None |
Frequency of cannabis use, past mo | — | 72.8 ± 57 | — | 81.6 ± 87 | None |
Cannabis consumed in past mo, g | — | 26.4 ± 46 | — | 38.0 ± 56 | None |
CAST score, past yr | — | 15.5 ± 3.9 | — | 17.4 ± 5.4 | None |
CAST score lifetime | — | 17.6 ± 3.6 | — | 19.0 ± 4.4 | None |
Regular cannabis use, yr | — | 5.7 ± 5.0 | — | 5.6 ± 3.9 | None |
Cannabis craving on test day | — | 5.5 ± 3.4 | — | 6.8 ± 3.9 | None |
Mood disorder diagnosis, no. (%) | 3 (20) | 5 (25) | 5 (33) | 3 (15) | None |
Anxiety disorder diagnosis, no. (%) | 3 (20) | 5 (25) | 3 (20) | 5 (25) | None |
Other substance use diagnosis, lifetime, no. (%) | 0 | 7 (35) | 0 | 7 (35) | None |
Other substances used in past mo, no. (%) | 0 | 7 (35) | 0 | 4 (20) | None |
Current cigarette smoker, no. (%) | 5 (33) | 9 (45) | 3 (20) | 16 (80) | Users v. nonusers§ |